Condition

Myelodysplastic Syndromes (MDS) clinical trials and research

• 10Clinical trials
• 3NIH research projects
• 26Countries

Newest Myelodysplastic Syndromes (MDS) clinical trials

All recruiting trials (10)

• Asia MDS Registry: Real-world Insights from Asia

  This registry collects real-world data on adults with myelodysplastic syndromes in Asia to see how they are diagnosed, treated, and what outcomes they experience.

  Recruiting Bristol-Myers Squibb · Singapore and 2 other locations · NCT07355478

• Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor

  This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT07238712

• Personalized dosing of azacytidine for patients with blood cancers

  This study is testing if adjusting the dose of azacytidine based on patients' genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes get better results with fewer side effects.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT06886425

• Evaluating the response to a biosimilar treatment for anemia in MDS patients

  This study is testing how well a new version of an anemia treatment works for people with Myelodysplastic Syndromes who have either responded to the original treatment before or are starting it for the first time.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06764511

• Combining ICP-248 with Azacitidine for treating Acute Myelogenous Leukemia

  This study is testing whether a new drug called ICP-248, when combined with azacitidine, can safely help people with Acute Myelogenous Leukemia feel better and improve their treatment outcomes.

  Recruiting at 22 sites Phase 1 Beijing InnoCare Pharma Tech Co., Ltd. · Orange, California and 21 other locations · NCT06656494

• Treatment for Myelodysplastic Syndromes with IDH1 Mutation

  This study is testing whether a new drug called ivosidenib can help people with myelodysplastic syndromes and an IDH1 mutation feel better compared to the standard treatment with azacitidine.

  Recruiting at 57 sites Phase 3 Servier · Denver, Colorado and 61 other locations · NCT06465953

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Using engineered immune cells with chemotherapy to treat blood cancers

  This study is testing if using special immune cells along with chemotherapy can help people with tough-to-treat blood cancers like B-cell lymphoma and leukemia feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05092451

• Improving cognitive function in older adults after stem cell transplant

  This study is testing if a special exercise program can help older adults who had a stem cell transplant think better and improve their brain health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT04898790

• Evaluating long-term safety of luspatercept for patients previously in other trials

  This study is testing the long-term safety of luspatercept for people with myelodysplastic syndromes, beta-thalassemia, and certain blood cancers who have already participated in other luspatercept trials.

  Recruiting at 27 sites Phase 3 Celgene · Los Angeles, California and 142 other locations · NCT04064060

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS

  A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).

  NIH research Yale University · New Haven, United States · NIH-11332844

• Targeting genetic defects in a type of blood disorder called myelodysplastic syndrome.

  This study is looking at how changes in the SF3B1 gene affect myelodysplastic syndromes (MDS), a condition that can cause problems with blood cell production, to help find new treatment options that could make life easier for patients with MDS.

  NIH research Yale University · New Haven, United States · NIH-11124840

• Understanding how SF3B1 mutations affect blood cell development in myelodysplastic syndromes.

  This study is looking at how changes in a specific gene (SF3B1) affect blood cell production in people with myelodysplastic syndromes (MDS), using advanced techniques to understand these changes at the single-cell level, which could help improve treatments for the condition.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11014391

Related topics

Quick answers

How many Myelodysplastic Syndromes (MDS) clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (6 trials), Australia (3 trials), France (3 trials), Italy (3 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 2, Phase 1: 1, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →